Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Biotechwantabe who wrote (3140)	11/5/2020 10:07:57 PM
From: Biotechwantabe	Read Replies (1) \| Respond to of 3557

Roche deal was a good way to increase supply; plus regeneron increasing capacity will pull in good rev/earnings. COVID volumes will decline over the next few years so no sense scaling up to much. Missing some opportunity now but not much you can do about that. Hopefully manufacturing goes better than expected. Still should put plan in place for next opportunity. BioGigA factory. Good earning Great science advancements Share looking inexpensive again. ROW sales need improvement.